Morgan Meredith A, Lawrence Theodore S
Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, Michigan.
Clin Cancer Res. 2015 Jul 1;21(13):2898-904. doi: 10.1158/1078-0432.CCR-13-3229.
DNA double-strand breaks are the critical lesions responsible for the majority of ionizing radiation-induced cell killing. Thus, the ability of tumor cells to elicit a DNA damage response following radiation, via activation of DNA repair and cell-cycle checkpoints, promotes radiation resistance and tumor cell survival. Consequently, agents that target these DNA damage response pathways are being developed to overcome radiation resistance. Overall, these agents are effective radiosensitizers; however, their mechanisms of tumor cell selectivity are not fully elucidated. In this review, we focus on the crucial radiation-induced DNA damage responses as well as clinical and translational advances with agents designed to inhibit these responses. Importantly, we describe how synthetic lethality can provide tumor cell-selective radiosensitization by these agents and expand the therapeutic window for DNA damage response-targeted agents used in combination with radiotherapy.
DNA双链断裂是导致大多数电离辐射诱导细胞死亡的关键损伤。因此,肿瘤细胞在辐射后通过激活DNA修复和细胞周期检查点引发DNA损伤反应的能力,促进了辐射抗性和肿瘤细胞存活。因此,正在开发针对这些DNA损伤反应途径的药物以克服辐射抗性。总体而言,这些药物是有效的放射增敏剂;然而,它们对肿瘤细胞的选择性作用机制尚未完全阐明。在本综述中,我们重点关注关键的辐射诱导DNA损伤反应,以及旨在抑制这些反应的药物在临床和转化方面的进展。重要的是,我们描述了合成致死性如何通过这些药物提供肿瘤细胞选择性放射增敏作用,并扩大与放疗联合使用的DNA损伤反应靶向药物的治疗窗口。